SCDARIC-33 by Regeneron Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval

SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia.

May 17, 2024 - 04:00

SCDARIC-33 is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Refractory Acute Myeloid Leukemia.

Read the original article

Tags:

Previous Article

Breaking bonds to form bonds: Rethinking the Chemistry of Cations

Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lu...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Four burning questions about the potential 85,000-worker Kaiser Permanente strike

STAT+: Four burning questions about the potential 85,00...

Sep 22, 2023

A research team airs the messy truth about AI in medicine — and gives hospitals a guide to fix it

A research team airs the messy truth about AI in medici...

Apr 27, 2023

STAT+: Antitrust lawsuit alleges UnitedHealth’s Optum pressured a California hospital to stop competing over physicians

STAT+: Antitrust lawsuit alleges UnitedHealth’s Optum p...

Nov 25, 2023